封面
市场调查报告书
商品编码
1447789

全球前列腺癌治疗市场规模、份额、成长分析,按药物(挤压化疗、生物疗法)、配销通路(医院药房、药房和零售药房)- 2024-2031 年行业预测

Global Prostate Cancer Treatment Market Size, Share, Growth Analysis, By Drug(Extruded Chemotherapy, Biological Therapy), By Distribution Channel(Hospitals Pharmacies, Drug Stores & Retail Pharmacies) - Industry Forecast 2024-2031

出版日期: | 出版商: SkyQuest | 英文 157 Pages | 商品交期: 3-5个工作天内

价格
简介目录

2022年全球前列腺癌治疗市场规模为120亿美元,预计将从2023年的130.4亿美元成长到2031年的254.2亿美元,预测期间(2024-2031年)复合CAGR为8.70%。

全球前列腺癌治疗市场呈现出一个充满活力的格局,伴随着重要的市场洞察,这主要是由前列腺癌的盛行率所推动的,前列腺癌是全世界男性最常诊断的癌症之一。市场的主要目标是为患有这种疾病的个人提供先进且有效的治疗选择。多种因素推动了市场的成长,包括人口老化、意识的提高以及早期诊断工作导致新疗法和药物的开发。然而,市场遇到了一些限制,例如治疗费用增加以及与前列腺癌治疗相关的潜在副作用,这可能会阻碍广泛采用。主要驱动因素包括人口老化、前列腺癌发病率上升、药物干预措施激增、对治疗选择的认识提高、研发资金增加、市场渗透率提高以及复杂管道药物的出现以及创新疗法的出现。此外,对前列腺癌治疗的需求不断增长,以及在非转移性去势抵抗性和转移性荷尔蒙初治前列腺癌中使用荷尔蒙疗法也有助于市场扩张。此外,发展中经济体呈现出未开发的潜力,在预测期内提供了利润丰厚的成长机会;然而,欠发达地区恢復期延长和前列腺癌药物需求疲软可能会阻碍市场成长。全球前列腺癌治疗市场面临的挑战包括需要更有针对性的治疗方法和不断发展的监管框架。儘管如此,透过药物标靶增强,该市场存在大量机会,随着市场的不断发展,这将显着提高个别患者的治疗精度。增加对研发工作的投资可能会导致开发出更有效的疗法,从而提高前列腺癌患者的生活品质和存活率。

目录

执行摘要

  • 市场概况
  • 命运之轮

研究方法论

  • 资讯采购
  • 二手和主要资料来源
  • 市场规模估计
  • 市场假设与限制

母公司市场分析

  • 市场概况
  • 市场规模
  • 市场动态
    • 司机
    • 机会
    • 限制
    • 挑战

主要市场洞察

  • 技术分析
  • 定价分析
  • 供应链分析
  • 价值链分析
  • 市场生态系统
  • 智慧财产权分析
  • 贸易分析
  • 启动分析
  • 原料分析
  • 创新矩阵
  • 管道产品分析
  • 总体经济指标
  • 顶级投资分析
  • 成功的关键因素
  • 竞争程度

市场动态与展望

  • 市场动态
    • 司机
    • 机会
    • 限制
    • 挑战
  • 监管环境
  • 波特分析
  • 对未来颠覆的特别见解

按药物分類的全球前列腺癌治疗市场

  • 市场概况
  • 挤压化疗
  • 生物疗法
  • 荷尔蒙疗法
  • 其他的

按配销通路分類的全球前列腺癌治疗市场

  • 市场概况
  • 医院药房
  • 药局和零售药局
  • 和网路药局

全球前列腺癌治疗市场规模(按地区)

  • 市场概况
  • 北美洲
    • 美国
    • 加拿大
  • 欧洲
    • 德国
    • 西班牙
    • 法国
    • 英国
    • 欧洲其他地区
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 拉丁美洲
    • 巴西
    • 拉丁美洲其他地区
  • 中东和非洲 (MEA)
    • 海湾合作委员会国家
    • 南非
    • MEA 的其余部分

竞争格局

  • 前 5 名玩家比较
  • 2021 年关键参与者的市场定位
  • 主要市场参与者所采取的策略
  • 最佳制胜策略
  • 近期市集活动
  • 主要公司市占率(%),2021年

主要公司简介

  • Ferring Pharmaceuticals Inc. (Switzerland)
  • GlaxoSmithKline Plc. (UK)
  • Ipsen Pharma (France)
  • AstraZeneca plc (UK)
  • F. Hoffmann-La Roche AG (Switzerland)
  • Astellas Pharma Inc (Japan)
  • Johnson & Johnson (US)
  • Bayer AG. (Germany)
  • Bristol-Myers Squibb Company (US)
  • Takeda Pharmaceutical Company Ltd (Japan)
  • Amgen Inc. (US)
  • Pfizer Inc (US)
  • Novartis AG (Switzerland)
  • Sanofi (France)
  • Merck & Co., Inc (US)
  • Eli Lilly and Company (US)
  • Gilead Sciences, Inc (US)
  • AbbVie Inc (US)
  • Celgene Corporation (US)
  • Teva Pharmaceutical Industries Ltd (Israel)
简介目录
Product Code: SQMIG35I2244

Global Prostate Cancer Treatment Market size was valued at USD 12 billion in 2022 and is poised to grow from USD 13.04 billion in 2023 to USD 25.42 billion by 2031, growing at a CAGR of 8.70% in the forecast period (2024-2031).

The global market for prostate cancer treatment presents a dynamic landscape accompanied by crucial market insights, driven primarily by the prevalence of prostate cancer, one of the most commonly diagnosed cancers in men worldwide. The market's main objective revolves around offering advanced and efficacious treatment options for individuals afflicted with this condition. Various factors fuel market growth, including the aging population, heightened awareness, and early diagnosis efforts leading to the development of novel treatments and medications. Nevertheless, the market encounters constraints such as elevated treatment expenses and potential side effects associated with prostate cancer therapies, which could impede widespread adoption. Key drivers encompass the aging demographic, escalating incidence rates of prostate cancer, proliferation of pharmaceutical interventions, heightened awareness regarding treatment options, increased research and development funding, enhanced market penetration, and the emergence of sophisticated pipeline drugs alongside the availability of innovative therapies. Additionally, the rising demand for prostate cancer treatments and the utilization of hormonal therapy in non-metastatic castration-resistant and metastatic hormone-naive prostate cancer scenarios contribute to market expansion. Furthermore, developing economies present untapped potentials, offering lucrative growth opportunities during the forecast period; however, prolonged recovery periods in underdeveloped regions and subdued demand for prostate cancer drugs may hinder market growth. Challenges in the global prostate cancer treatment market include the necessity for a more tailored treatment approach and evolving regulatory frameworks. Nonetheless, substantial opportunities exist in this market through drug targeting enhancements, which significantly augment treatment precision for individual patients as the market continues to evolve. Increased investment in research and development endeavors could lead to the development of more effective therapies, thereby enhancing the quality of life and survival rates for prostate cancer patients.

Top-down and bottom-up approaches were used to estimate and validate the size of the Prostate Cancer Treatment Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Prostate Cancer Treatment Market Segmental Analysis

The global prostate cancer treatment market is segmented on the basis of drug, distribution channel, and region. By drug, the market is segmented into chemotherapy, biological therapy, hormone therapy, and others. By distribution channel, the market is segmented into hospitals pharmacies, drug stores & retail pharmacies, and online pharmacies. By region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Drivers of the Prostate Cancer Treatment Market

The rising prevalence of prostate cancer is driven by various factors, including an aging global population and improved diagnostic techniques, leading to increased awareness and earlier detection. As the incidence of prostate cancer is expected to rise, particularly among older men, there is a growing demand for effective treatment options in the global market.

Restraints in the Prostate Cancer Treatment Market

the market faces challenges such as high costs associated with targeted therapies and immunotherapies, which can pose affordability issues for patients and healthcare providers alike. Despite the promise of these advanced therapies in improving patient outcomes, access remains limited due to financial constraints. Addressing cost barriers is crucial to ensure widespread access to potentially life-saving treatments for prostate cancer.

Market Trends of the Prostate Cancer Treatment Market

A notable trend in the market is the adoption of personalized medicine approaches in prostate cancer treatment, which involves tailoring treatments based on individual genetic and molecular characteristics. This approach enhances treatment accuracy and reduces the risk of unnecessary interventions, thereby minimizing side effects and improving overall outcomes. Popular biochemical tests such as the Prostate Health Index (PHI), Oncotype DX Genomic Prostate Score, and Prolaris test are utilized to identify genetic variations in cancer cells, guiding treatment decisions. Targeted therapies like olaparib and rucaparib, which specifically target tumors with DNA repair process alterations, exemplify this personalized approach and demonstrate potential in treating advanced prostate cancer.

Table of Contents

Executive Summary

  • Market Overview
  • Wheel of Fortune

Research Methodology

  • Information Procurement
  • Secondary & Primary Data Sources
  • Market Size Estimation
  • Market Assumptions & Limitations

Parent Market Analysis

  • Market Overview
  • Market Size
  • Market Dynamics
    • Drivers
    • Opportunities
    • Restraints
    • Challenges

Key Market Insights

  • Technology Analysis
  • Pricing Analysis
  • Supply Chain Analysis
  • Value Chain Analysis
  • Ecosystem of the Market
  • IP Analysis
  • Trade Analysis
  • Startup Analysis
  • Raw Material Analysis
  • Innovation Matrix
  • Pipeline Product Analysis
  • Macroeconomic Indicators
  • Top Investment Analysis
  • Key Success Factor
  • Degree of Competition

Market Dynamics & Outlook

  • Market Dynamics
    • Drivers
    • Opportunities
    • Restraints
    • Challenges
  • Regulatory Landscape
  • Porters Analysis
    • Competitive rivalry
    • Threat of Substitute Products
    • Bargaining Power of Buyers
    • Threat of New Entrants
    • Bargaining Power of Suppliers
  • Skyquest Special Insights on Future Disruptions
    • Political Impact
    • Economic Impact
    • Social Impact
    • Technical Impact
    • Environmental Impact
    • Legal Impact

Global Prostate Cancer Treatment Market by Drug

  • Market Overview
  • Extruded Chemotherapy
  • Biological Therapy
  • Hormone Therapy
  • and Others

Global Prostate Cancer Treatment Market by Distribution Channel

  • Market Overview
  • Hospitals Pharmacies
  • Drug Stores & Retail Pharmacies
  • and Online Pharmacies

Global Prostate Cancer Treatment Market Size by Region

  • Market Overview
  • North America
    • USA
    • Canada
  • Europe
    • Germany
    • Spain
    • France
    • UK
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Latin America
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (MEA)
    • GCC Countries
    • South Africa
    • Rest of MEA

Competitive Landscape

  • Top 5 Player Comparison
  • Market Positioning of Key Players, 2021
  • Strategies Adopted by Key Market Players
  • Top Winning Strategies
    • By Development
    • By Company
    • By Year
  • Recent Activities in the Market
  • Key Companies Market Share (%), 2021

Key Company Profiles

  • Ferring Pharmaceuticals Inc. (Switzerland)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • GlaxoSmithKline Plc. (UK)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Ipsen Pharma (France)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • AstraZeneca plc (UK)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • F. Hoffmann-La Roche AG (Switzerland)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Astellas Pharma Inc (Japan)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Johnson & Johnson (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Bayer AG. (Germany)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Bristol-Myers Squibb Company (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Takeda Pharmaceutical Company Ltd (Japan)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Amgen Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Pfizer Inc (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Novartis AG (Switzerland)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Sanofi (France)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Merck & Co., Inc (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Eli Lilly and Company (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Gilead Sciences, Inc (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • AbbVie Inc (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Celgene Corporation (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Teva Pharmaceutical Industries Ltd (Israel)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments